Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFκB p65

详细信息    查看全文

• 作者：Shihui Li (1)
  Fang Xue (1)
  Zhiyong Cheng (1)
  Xiaoyang Yang (2)
  Suyun Wang (1)
  Fengyong Geng (3)
  Ling Pan (1)
  
• 关键词：Artesunate ; Multiple myeloma ; Apoptosis ; Proliferation ; Nuclear factor kappa B
• 刊名：International Journal of Hematology
• 出版年：2009
• 出版时间：November 2009
• 年：2009
• 卷：90
• 期：4
• 页码：513-521
• 全文大小：389KB
• 参考文献：1. Fermand JP, Ravaud P, Chevret S, Divine M, Leblond V, Belanger C, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood. 1998;92:3131-.
  2. Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875-3. CrossRef
  3. Singhal S, Powles R, Sirohi B, Treleaven J, Kulkarni S, Mehta J. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma. Bone Marrow Transplant. 2002;30:673-. CrossRef
  4. Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 1999;341:1565-1. CrossRef
  5. Singhal S, Mehta J. Novel therapies in myeloma. Int J Hematol. 2003;77:226-1. CrossRef
  6. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Apoptotic signaling induced by immuno-modulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002;99:4525-0. CrossRef
  7. Wu KL, Beksac M, van Droogenbroeck J, Amadori S, Zweegman S, Sonneveld P. Phase II multicenter study of arsenic trioxide, ascorbic acid and dexamethasone in patients with relapsed or refractory multiple myeloma. Haematologica. 2006;91:1722-.
  8. Pei XY, Dai Y, Grant S. Synergistic induction of oxidative injury and apoptosis in human multiple myeloma cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitors. Clin Cancer Res. 2004;10:3839-2. CrossRef
  9. Richardson PG, Barlogie B, Berenson J, Irwin D, Stadtmauer EA, Facon T, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003;348:2609-7. CrossRef
  10. Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med. 2005;352:2487-8. CrossRef
  11. Oakervee HE, Popat R, Curry N, Smith P, Morris C, Drake M, et al. PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol. 2005;129:755-2. CrossRef
  12. Adjuik M, Babiker A, Garner P, Olliaro P, Taylor W, White N. Artesunate combinations for treatment of malaria: meta-analysis. Lancet. 2004;363:9-7. CrossRef
  13. Cumming JN, Ploypradith P, Posner GH. Antimalarial activity of artemisinin (qinghaosu) and related trioxanes: mechanism(s) of action. Adv Pharmacol. 1997;37:253-7. CrossRef
  14. Dorsey G, Vlahos J, Kamya MR, Staedke SG, Rosenthal PJ. Prevention of increasing rates of treatment failure by combining sulfadoxine-pyrimethamine with artesunate or amodiaquine for the sequential treatment of malaria. J Infect Dis. 2003;188:1231-. CrossRef
  15. Van Vugt M, Leonardi E, Phaipun L, Slight T, Thway KL, McGready R, et al. Treatment of uncomplicated multidrug-resistant falciparum malaria with artesunate–atovaquone–proguanil. Clin Infect Dis. 2002;35:1498-04. CrossRef
  16. Efferth T, Dunstan H, Sauerbrey A, Miyachi H, Chitambar CR. The anti-malarial artesunate is also active against cancer. Int J Oncol. 2001;18:767-3.
  17. Efferth T, Sauerbrey A, Olbrich A, Gebhart E, Rauch P, Weber HO, et al. Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 2003;64:382-4. CrossRef
  18. Efferth T, Benakis A, Romero-Rodriguez MR, Tomicic M, Rauh R, Steinbach D, et al. Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med. 2004;37:998-009. CrossRef
  19. Posner GH, McRiner AJ, Paik IH, Sur S, Borstnik K, Xie S, et al. Anticancer and antimalarial efficacy and safety of artemisinin-derived trioxane dimers in rodents. J Med Chem. 2004;47:1299-01. CrossRef
  20. Suzuki A, Shiraki K. Tumor cell “dead or alive- caspase and surviving regulate cell death, cell cycle and cell survival. Histol Histopathol. 2001;16:583-3.
  21. Mitsiades N, Mitsiades CS, Poulaki V, Chauhan D, Richardson PG, Hideshima T, et al. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002;99:4079-6. CrossRef
  22. Berenson JR, Ma HM, Vescio R. The role of nuclear factor-kappaB in the biology and treatment of multiple myeloma. Semin Oncol. 2001;28:626-3. CrossRef
  23. Hideshima T, Chauhan D, Schlossman R, Richardson P, Anderson KC. The role of tumor necrosis factor alpha in the pathophysiology of human multiple myeloma: therapeutic applications. Oncogene. 2001;20:4519-7. CrossRef
  24. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002;277:16639-7. CrossRef
  25. Keifer JA, Guttridge DC, Ashburner BP, Baldwin AS Jr. Inhibition of NF-кB activity by thalidomide through suppression of IкB kinase activity. J Biol Chem. 2001;276:22382-. CrossRef
  26. Zhou LF, Zhu Y, Cui XF, Xie WP, Hu AH, Yin KS. Arsenic trioxide, a potent inhibitor of NF-kappaB, abrogates allergen-induced airway hyperresponsiveness and inflammation. Respir Res. 2006;20:146-. CrossRef
  27. Lemarie A, Morzadec C, Mérino D, Micheau O, Fardel O, Vernhet L. Arsenic trioxide induces apoptosis of human monocytes during macrophagic differentiation through nuclear factor-kappaB related survival pathway down-regulation. J Pharmacol Exp Ther. 2006;316:304-4. CrossRef
  28. Liu WM, Strauss SJ, Chaplin T, Shahin S, Propper DJ, Young BD, et al. s-Thalidomide has a greater effect on apoptosis than angiogenesis in a multiple myeloma cell line. Hematol J. 2004;5:247-4. CrossRef
  29. Russo SM, Tepper JE, Baldwin AS Jr, Liu R, Adams J, Elliott P, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NF-kappaB. Int J Radiat Oncol Biol Phys. 2001;50:183-3.
  30. St Croix B, Florenes VA, Rak JW, Flanagan M, Bhattacharya N, Slingerland JM, et al. Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents. Nat Med. 1996;2:1204-0. CrossRef
  31. St Croix B, Sheehan C, Rak JW, Fl?renes VA, Slingerland JM, Kerbel RS. E-Cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27 Kip1. J Cell Biol. 1998;142:557-1. CrossRef
  
• 作者单位：Shihui Li (1)
  Fang Xue (1)
  Zhiyong Cheng (1)
  Xiaoyang Yang (2)
  Suyun Wang (1)
  Fengyong Geng (3)
  Ling Pan (1)
  
  1. Department of Hematology, The Second Hospital of Hebei Medical University, 215, Heping Xi Road, 050000, Shijiazhuang City, People’s Republic of China
  2. Department of Hematology, Affiliated Haikou Hospital, Xiangya School of Medicine, Central South University, Haikou Municipal Hospital, 570208, Haikou, People’s Republic of China
  3. Department of General Surgery, Aviation Central Hospital, No. 3, Anwai Bei Yuan, ChaoYang District, 100012, Peking City, People’s Republic of China
  

文摘

The initial treatment of multiple myeloma (MM) experienced a paradigm shift, in the past decade, with the introduction of novel agents such as thalidomide, lenalidomide and bortezomib, leading to improved outcomes. High dose therapy and autologous stem cell transplantation remain an important therapeutic option for patients with MM eligible for the procedure. However, most of these treatment regimens are too expensive for Chinese patients. Therefore, we investigated the effects of artesunate, which is commonly used in the treatment of severe malaria, on inhibition of proliferation and induction of apoptosis of a mouse myeloma cell line SP2/0. The growth inhibition of SP2/0 cell proliferation induced by artesunate (ART) treatment was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method and the rate of apoptosis and cell cycle changes induced by ART were analyzed by flow cytometry. ART-induced morphology changes of apoptosis in SP2/0 cells, as observed by light and transmission electron microscopy. Additionally, DNA laddering, which is a hallmark of apoptosis, was observed by agarose gel electrophoresis of DNA harvested from SP2/0 cells treated with ART. The levels of nuclear factor kappa B p65 (NFκB p65) protein in nucleus and the inhibitor of NFκB (IκBα) in the cytoplasm were measured by western blot analysis and ELISA to evaluate NFκB p65 transcription activity indirectly. The results show that artesunate inhibited the proliferation and induced apoptosis of SP2/0 cells in a dose- and time-dependent manner. Artesunate also increased the proportion of SP2/0 cells in G0/G1 phase, while decreased the proportion of cells in G2/M or S phase. Additionally, artesunate treatment decreased the level of NFκB p65 protein in the nucleus, while increased the level of IκBα protein in the cytoplasm. The present result is the first report to show that artesunate may be useful in the treatment of MM.